Publications by authors named "Johan Aschan"

Claim this Profile
O
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Fredrik Schjesvold, Pawel Robak, Ludek Pour, Johan Aschan, Pieter Sonneveld

Future Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Peter Hillmen, Joris Diels, Nollaig Healy, Wafae Iraqi, Johan Aschan

Haematologica· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
Katarina Uttervall, Adil D Duru, Johan Lund, Johan Liwing, Gösta Gahrton, Johan Aschan

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Johan Liwing, Katarina Uttervall, Johan Lund, Anders Aldrin, Cecilie Blimark, Johan Aschan

Br J Haematol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Johan Lund, Katarina Uttervall, Johan Liwing, Gösta Gahrton, Evren Alici, Johan Aschan

Eur J Haematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Katarina Uttervall, Johannes Admasie, Evren Alici, Johan Lund, Johan Liwing, Johan Aschan

Acta Haematol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
John Hornberger, Joseph Rickert, Ravinder Dhawan, Johan Liwing, Johan Aschan

Eur J Haematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Jochen Casper, Daniel Wolff, Wolfgang Knauf, Igor W Blau, Tapani Ruutu, Johan Aschan

J Clin Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Lisbeth Barkholt, Evren Alici, Reka Conrad, Tolga Sutlu, Mari Gilljam, Johan Aschan

Immunotherapy· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation.
Gayane Avetisyan, Johan Aschan, Moustapha Hassan, Per Ljungman

Transplantation· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemorrhagic cystitis: a retrospective single-center survey.
Zuzana Hassan, Mats Remberger, Petter Svenberg, Maria Elbander, Brigitta Omazic, Johan Aschan

Clin Transplant· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk assessment in haematopoietic stem cell transplantation: conditioning.
Johan Aschan

Best Pract Res Clin Haematol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic haematopoietic stem cell transplantation: current status and future outlook.
Johan Aschan

Br Med Bull· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis.
Staffan Wahlin, Johan Aschan, Mikael Björnstedt, Ulrika Broomé, Pauline Harper

J Hepatol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Olle Ringdén, Mehmet Uzunel, Ida Rasmusson, Mats Remberger, Berit Sundberg, Johan Aschan

Transplantation· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center.
Olle Ringdén, Mats Remberger, Britt-Marie Svahn, Lisbeth Barkholt, Jonas Mattsson, Johan Aschan

Transplantation· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloablative and immunosuppressive properties of treosulfan in mice.
Fredrik Sjöö, Zuzana Hassan, Manuchehr Abedi-Valugerdi, Laimonas Griskevicius, Christina Nilsson, Johan Aschan

Exp Hematol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.
Per Ljungman, Lena Perez-Bercoff, Jerker Jonsson, Gayane Avetisyan, Elda Sparrelid, Johan Aschan

Haematologica· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors.
Petter Svenberg, Mats Remberger, Johan Svennilson, Jonas Mattsson, Katarina Leblanc, Johan Aschan

Biol Blood Marrow Transplant· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus.
Kajsa Larsson, Johan Aschan, Mats Remberger, Olle Ringdén, Jacek Winiarski

Transplantation· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Mats Remberger, Gunilla Kumlien, Johan Aschan, Lisbeth Barkholt, Patrik Hentschke

Biol Blood Marrow Transplant· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
Per Ljungman, Kajsa Larsson, Gunilla Kumlien, Johan Aschan, Lisbeth Barkholt

Scand J Infect Dis· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation.
Mehmet Uzunel, Jonas Mattsson, Mats Brune, Jan-Erik Johansson, Johan Aschan

Blood· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care.
Britt-Marie Svahn, Mats Remberger, Karl-Erik Myrbäck, Katarina Holmberg, Britta Eriksson, Johan Aschan

Blood· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors.
Patrik Hentschke, Mats Remberger, Jonas Mattsson, Lisbeth Barkholt, Johan Aschan

Transplantation· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis